| Title: | Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort |
| Journal: | Translational Psychiatry |
| Published: | 26 Jun 2021 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/34226496/ |
| DOI: | https://doi.org/10.1038/s41398-021-01482-9 |
| URL: | https://www.nature.com/articles/s41398-021-01482-9.pdf |
| Citations: | 7 (2 in last 2 years) as of 8 Aug 2024 |
Publication 9768
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Weight gain and metabolic complications are major adverse effects of many psychotropic drugs. We aimed to understand how socio-economic status (SES), defined as the Swiss socio-economic position (SSEP), is associated with cardiometabolic parameters after initiation of psychotropic medications known to induce weight gain. Cardiometabolic parameters were collected in two Swiss cohorts following the prescription of psychotropic medications. The SSEP integrated neighborhood-based income, education, occupation, and housing condition. The results were then validated in an independent replication sample (UKBiobank), using educational attainment (EA) as a proxy for SES. Adult patients with a low SSEP had a higher risk of developing metabolic syndrome over one year versus patients with a high SSEP (Hazard ratio (95% CI) = 3.1 (1.5-6.5), n = 366). During the first 6 months of follow-up, a significant negative association between SSEP and body mass index (BMI), weight change, and waist circumference change was observed (25 ≤ age < 65, n = 526), which was particularly important in adults receiving medications with the highest risk of weight gain, with a BMI difference of 0.86 kg/m2 between patients with low versus high SSEP (95% CI: 0.03-1.70, n = 99). Eventually, a causal effect of EA on BMI was revealed using Mendelian randomization in the UKBiobank, which was notably strong in high-risk medication users (beta: −0.47 SD EA per 1 SD BMI; 95% CI: −0.46 to −0.27, n = 11,314). An additional aspect of personalized medicine was highlighted, suggesting the patients' SES represents a significant risk factor. Particular attention should be paid to patients with low SES when initiating high cardiometabolic risk psychotropic medications.</p>
15 Authors
- Céline Dubath
- Mehdi Gholam-Rezaee
- Jennifer Sjaarda
- Axel Levier
- Nuria Saigi-Morgui
- Aurélie Delacrétaz
- Anaïs Glatard
- Radoslaw Panczak
- Christoph U. Correll
- Alessandra Solida
- Kerstin Jessica Plessen
- Armin von Gunten
- Zoltan Kutalik
- Philippe Conus
- Chin B. Eap
1 Application
| Application ID | Title |
|---|---|
| 16389 | Exploring Diet/Lifestyle factors as causes and modifiers of genetic determinants of obesity and metabolic traits |
Enabling scientific discoveries that improve human health